| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Nuvectis Pharma, Inc. (NVCT) have been net buyers, picking up 62,500 shares worth roughly $1.2M on balance.
Classified under Biotechnology (Health Care sector), NVCT's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 3.69M | $84.06M | - | |
| 10% | 3.19M | $72.62M | - | |
| Other | 1.81M | $41.17M | - | |
| Other | 1.79M | $40.86M | - | |
| VP | 200.1K | $4.56M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2022 | Bentsur Ron64 | Chairman &CEO | Buy | 8,500 | $6.34 | $53,890.00 | +0.3% | +157.6% | +133.3% | |
| Feb 7, 2022 | Bentsur Ron64 | Chairman &CEO | Buy | 232,500 | $4.96 | $1,153,145.00 | +2.1% | +89.4% | +37.0% | |
| Feb 7, 2022 | Poradosu Enrique70 | Chief Science &Business Off | Buy | 4,600 | $3.44 | $15,834.00 | +0.2% | +89.4% | +37.0% | |
| Feb 7, 2022 | Shemesh Shay72 | Chief Development Officer | Buy | 2,946 | $3.41 | $10,033.62 | +0.1% | +89.4% | +37.0% |